

Contents

Introduction	1
Aim of the Work	3
Chronic Kidney Disease	
• Introduction	4
• Defining Chronic Kidney Disease And Developing A Staging System	4
• Risk Factors of Chronic Kidney Disease	7
• Detection of Individuals at Higher Risk of Developing Chronic Kidney Disease	7
• Diagnosis of Chronic Renal Failure	9
• Clinical Picture of CKD	9
• Detecting Kidney Damage	11
• Assessment of Renal Function	14
Anemia of Chronic Kidney Disease	
• Introduction	17
• Prevalence of Anemia In Chronic Kidney Disease	18
• Pathogenesis	20
• Inflammation and Anemia in Patients with Chronic Kidney Disease	23
• Malnutrition and Anemia in Patients with CKD	24
• Anemia and Cardiovascular Diseases in CKD	26
• Association Between Anemia And Left Ventricular Hypertrophy In Chronic Kidney Disease	27
• Post Transplantation Anemia	32
• Diagnosis of Anemia of Chronic Kidney Disease	35
• Defining the Optimal Target Haemoglobin Concentration for Chronic Kidney Disease Patients	37
Conventional Treatment for Anemia of Chronic Kidney Disease	
• Introduction	39
• Erythropoietin	39
• Recombinant Human Erythropoietin (Epoetin)	40
• History of Erythropoiesis Stimulating Agents (ESAs)	42

• Pharmacokinetic Differences	43
• Approved Indications And Dosing	43
• Extended Dosing Intervals	44
• Advantages of ESAs	45
• Mechanisms of Organ Protection by Erythropoiesis Stimulating Agents (ESAs)	48
• Advantage of Early Correction of Anemia in Patients With CKD	49
• Erythropoietin Use In Treatment of Anemia In Patients Receiving Peritoneal Dialysis	49
• Risks of Erythropoiesis Stimulating Agents (ESAs)	50
• Erythropoietin resistance	52
• Adjuvant Therapy in Patients Treated With rHuEpo	55
• IL-6 As A Therapeutic Target	56
• Iron Deficiency Anemia In Patients With CKD	57
• Physiology of Iron Metabolism	58
• Laboratory Assessment of Erythropoiesis and Iron Status	61
• Iron Deficiency and Estimation of Iron Status in Chronic Kidney Disease	65
• Iron therapy for treatment of anemia of CKD	66
• Risks of Iron Supplementation	71
• NKF-DOQI Clinical practice Guidelines	73
• Iron Support	73
• Dialysis-Related Carnitine Disorder and Levocarnitine Pharmacology	76

New Treatment for Anemia of Chronic Kidney Disease

• Introduction	83
• Darbepoetin Alfa	84
• Continuous Erythropoiesis Receptor Activator	85
• Synthetic Erythropoiesis Protein	90
• Erythropoietin Fusion Protein	93
• Erythropoietin-Mimetic Peptides	94
• GATA Inhibition	98
• Haemopoietic Cell Phosphatase Inhibitors	98
• Hypoxia Inducible Factor α Stabilisers	100